|
Feb 04, 2021
|
Dynavax Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
|
Feb 04, 2021
|
Dynavax and Serum Institute of India Announce First Participant Dosed in a Phase 1 Clinical Trial Evaluating an Improved Tdap Vaccine Adjuvanted with CpG 1018
|
|
|
Feb 01, 2021
|
Dynavax Announces Exercise of Option to Reserve Additional CpG 1018 to Produce 40 Million Doses of Valneva's Inactivated, Adjuvanted COVID-19 Vaccine Candidate for the UK Government
|
|
|
Feb 01, 2021
|
Dynavax and CEPI Announce $99 Million in Funding for CpG 1018 Adjuvant Manufacturing to Support the Global COVID-19 Response
|
|
|
Feb 01, 2021
|
Clover and Dynavax Announce Planned Global Phase 2/3 Efficacy Trial of Adjuvanted COVID-19 Vaccine Candidate
|
|
|
Jan 25, 2021
|
Medigen Vaccine Biologics COVID-19 Vaccine Adjuvanted with Dynavax's CpG 1018 Announces First Participant Dosed in Phase 2 Clinical Trial in Taiwan
|
|
|
Jan 20, 2021
|
Dynavax Appoints Kelly MacDonald as Chief Financial Officer
|
|
|
Jan 07, 2021
|
Dynavax Announces Final Immunogenicity and Interim Safety Results from Clinical Trial Evaluating HEPLISAV-B in Patients Undergoing Hemodialysis
|
|
|
Jan 06, 2021
|
Dynavax to Present at the H.C. Wainwright Virtual BioConnect 2021 Conference
|
|
